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majority of cardiac surgeons, and con-
sequently our findings reflect a ‘real-
world’ situation.’’
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Letters to the EditorCONTEGRA AND
EXTRACARDIAC FONTAN
To the Editor:
We read with the greatest interest
the article entitled ‘‘Feasibility of the
Extracardiac Conduit Fontan Proce-
dure in Patients Weighing Less than
10 Kilograms.’’1 After congratulating
the authors for their excellent work,
we have a few comments.
As a Fontan Conduit, they used poly-
tetrafluoroethylene (Gore-Tex; WL
Gore & Associates Inc, Flagstaff, Ariz)
(14–20 mm in diameter) King Faisal
Specialist Hospital and Research Center
in Jeddah, used Contegra valved con-
duits in 4 patients for inferior vena
cava–right pulmonary artery connection
(Fontan). They speculated that an
additional benefit of using the Contegra
xenograft couldbe that itprovidesacom-
petent valve in the Fontan circulation,
which might help by reducing the rever-
sal of flow and maintaining better
forward flow into the pulmonary
circulation. The concern was whether
the valve, in a nonpulsatile, passive Fon-
tan circulation, would facilitate smooth
antegradeflow into thepulmonary circu-The Journalation or act as a source of resistance to
the flow. The findings that none of their
patients had hepatomegaly or ascites on
physical examination and that the post-
operative echocardiograms showed ex-
cellent antegrade flow in the inferior
vena cava, which also was not dilated,
and minimal flow reversal in the hepatic
veins support the facilitation of smooth
forward flow. They presented a new op-
tion for constructing an extracardiac
Fontan connection with the Contegra
xenograft that has not been previously
published.Their earlyechocardiographic
results supported the idea of minimiz-
ing the reversal of infradiaphragmatic
venous flow, decreasing hepatic con-
gestion, and possibly reducing the de-
velopment of ascites.2 They do have
a way of assessing the conduit size by
using Rowlatt and colleagues’ chart.3
The authors routinely administered 5
mg/kg ticlopidine as antiplatelet ther-
apy.Warfarinwas not used even though
they had a patient with arteriovenous
valve replacement. How did they con-
trol the thrombogenic potential here?
Measurement of the lower lobe in-
dex is an important adjunct to evaluate
candidates for the Fontan operation.
The predictive value of the Nakata in-
dex is less informative than the lower
lobe index, which was introduced to
optimize the preoperative selection of
Fontan candidates. Lower lobe index
may be more predictive to evaluate
the adequacy of the pulmonary vascu-
lar tree, given that central pulmonary
arteries used to calculate the Nakata in-
dex can be enlarged before or during
the Fontan operation.4
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Reply to the Editor:
We appreciate Dr Sersar’s com-
ments on our recent article, ‘‘Feasibil-
ity of the Extracardiac Conduit Fontan
Procedure in Patients Weighing Less
than 10 Kilograms.’’ These comments
raise several questions concerning the
following: (1) choice of conduit type,
(2) anticoagulation therapy after the
Fontan procedure, and (3) examination
of the pulmonary arteries for evaluat-
ing the pulmonary vascular tree.
In our article, we describe our strat-
egy for the extracardiac Fontan opera-
tion without fenestration. Our strategy
aimed to eliminate cyanosis as soon as
possible. Fenestration might reduce
the duration of pleural drainage but
cannot eliminate cyanosis even after
the Fontan procedure. We mentioned
in the article that peritoneal drainage
might be able to reduce the duration
of pleural drainage in small children
in particular. In addition to the obvious
purpose of the drainage of ascites it-
self, drainage of ascites also results in
the drainage of the inflammatory fac-
tors present in the ascites.1 In our se-
ries at least, there were no patients
with recurrent ascites after the cessa-
tion of the initial peritoneal drainage.
We have a chance to use a Contegra
conduit2 if this conduit is an attractive
option for reducing ascites and pleural
effusion. However, the use of this
conduit for the Fontan operation is
not permitted in Japan. The fate of
the conduit as a xenograft, especially
in terms of obstruction of conduit and
durability of valve function, over the
long term should be investigated.ery c Volume 136, Number 5 1393
